dpp 4 inhibitor and glp 1 agonist Mechanisms of dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like DPP4 Inhibitors vs GLP-1 Agonists

While robust clinical trial data specific to these combinations continues to emerge, the physiological rationale and supporting evidence from component studies provide a sound basis for clinical application in appropriately selected patients

A., Wesson, S

Fatigue accompanied by other concerning symptoms including: Persistent dizziness, lightheadedness, or fainting Rapid or irregular heartbeat Shortness of breath or chest pain Severe or unrelenting nausea and vomiting Inability to keep down food or fluids for more than 24 hours Dark urine, markedly reduced urination, or swelling (signs of dehydration or kidney problems) Yellowing of skin or eyes Severe abdominal pain Mood changes, depression, or difficulty concentrating Signs of potential complications require immediate attention: Stop the medication and seek urgent medical care if you experience severe abdominal pain (especially radiating to the back) which could suggest pancreatitis Stop the medication and seek urgent care if you develop symptoms of severe allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing) Symptoms suggesting gallbladder disease (right upper abdominal pain, especially after eating) Hypoglycemia in patients taking diabetes medications (shakiness, sweating, confusion) Inability to meet nutritional needs despite best efforts, or unintentional weight loss exceeding recommended rates (generally more than 1-2 pounds per week after the initial period)

Back Lasker Foundation (2024) 'GLP-1-based therapy for obesity'

Harkavyi A, Whitton PS